2826 Stock Overview
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Tibet AIM Pharm. Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.46 |
| 52 Week High | CN¥13.28 |
| 52 Week Low | CN¥5.57 |
| Beta | 0.31 |
| 1 Month Change | 2.30% |
| 3 Month Change | -26.69% |
| 1 Year Change | -23.37% |
| 3 Year Change | -6.10% |
| 5 Year Change | -30.83% |
| Change since IPO | -3.09% |
Recent News & Updates
Shareholder Returns
| 2826 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.7% | -2.0% | -2.7% |
| 1Y | -23.4% | -17.1% | -18.2% |
Return vs Industry: 002826 underperformed the CN Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 002826 underperformed the CN Market which returned -17.2% over the past year.
Price Volatility
| 2826 volatility | |
|---|---|
| 2826 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 11.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002826's share price has been volatile over the past 3 months.
Volatility Over Time: 002826's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 447 | Ke Xu | www.emyy.cn |
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; and NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc. It also provides Carbetocin injections for prevention of postpartum hemorrhage; Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems.
Tibet AIM Pharm. Inc. Fundamentals Summary
| 2826 fundamental statistics | |
|---|---|
| Market cap | CN¥1.61b |
| Earnings (TTM) | CN¥46.78m |
| Revenue (TTM) | CN¥803.27m |
34.5x
P/E Ratio2.0x
P/S RatioIs 2826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2826 income statement (TTM) | |
|---|---|
| Revenue | CN¥803.27m |
| Cost of Revenue | CN¥425.48m |
| Gross Profit | CN¥377.78m |
| Other Expenses | CN¥331.01m |
| Earnings | CN¥46.78m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 47.03% |
| Net Profit Margin | 5.82% |
| Debt/Equity Ratio | 1.3% |
How did 2826 perform over the long term?
See historical performance and comparison